Esperion Therapeutics (ESPR) FCF Margin (2019 - 2026)

Esperion Therapeutics has reported FCF Margin for 8 years, with the latest figure at 34.84% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin fell 3.0% year-over-year to 34.84%; the trailing twelve-month figure through Mar 2026 stood at 4.44% (up 3405.0% YoY), and the FY2025 full-year result was 3.29%, up 382.0% from the prior year.
• FCF Margin for Q1 2026 stood at 34.84%, down from 26.75% in the prior quarter.
• The five-year high for FCF Margin was 38.94% in Q1 2024, with the low at 268.2% in Q2 2022.
• Historically, FCF Margin has averaged 93.73% across 5 years, with a median of 56.89% in 2023.
• The largest YoY upside for FCF Margin was 90942 bps in 2022 against a maximum downside of 15048 bps in 2022.
• Esperion Therapeutics' FCF Margin stood at 225.7% in 2022, then jumped by 49 bps to 114.9% in 2023, then surged by 56 bps to 50.11% in 2024, then jumped by 153 bps to 26.75% in 2025, then plunged by 230 bps to 34.84% in 2026.
• The last three FCF Margin figures came in at 34.84% (Q1 2026), 26.75% (Q4 2025), and 4.91% (Q3 2025), per Business Quant data.